항암화학요법에 의한 말초신경병과 통증

키워드

참고문헌 (68)

1. Cavaletti G, "Chemotherapy-induced peripheral neurotoxicity", Curr Opin Neurol, 28, pp.500~507 (2015)
2. Cavaletti G, "Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity", Expert Opin Pharmacother, 19, pp.113~121 (2018)
3. Hershman DL, "Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers:American Society of Clinical Oncology clinical practice guideline", J Clin Oncol, 32, pp.1941~1967 (2014)
4. Argyriou AA, "The Toxic Neuropathy Consortium of the Peripheral Nerve Society", J Peripher Nerv Syst, 24, pp.S4~S5 (2019)
5. Seretny M, "Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis", Pain, 155, pp.2461~2470 (2014)
6. Majithia N, "National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons", Support Care Cancer, 24, pp.1439~1447 (2016)
7. Ness KK, "Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude lifetime cohort study", Arch Phys Med Rehabil, 4, pp.1451~1457 (2013)
8. Kolb NA, "The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling", JAMA Neurol, 73, pp.860~866 (2016)
9. Dilruba S, "Platinum-based drugs: past, present and future", Cancer Chemother Pharmacol, 77, pp.1103~1124 (2016)
10. McDonald ES, "Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling", Neurobiol Dis, 9, pp.220~233 (2002)
11. Wang XM, "Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy", Cytokine, 59, pp.3~9 (2012)
12. Glendenning JL, "Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer", Cancer, 116, pp.2322~2331 (2010)
13. Albers JW, "Interventions for preventing neuropathy caused by cisplatin and related compounds", Cochrane Database Syst Rev, 31, pp.CD005228~ (2014)
14. Krishnan AV, "Oxaliplatin-in duced neurotoxicity and the development of neuropathy", Muscle Nerve, 32, pp.51~60 (2005)
15. Gurney H, "Original article: five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma", Ann Oncol, 1, pp.427~433 (1990)
16. Wilson RH, "Acute oxaliplatin-induced peripheral nerve hyperexcitability", J Clin Oncol, 20, pp.1767~1774 (2002)
17. Heide R, "Axonal excitability changes and acute symptoms of oxaliplatin treatment: in vivo evidence for slowed sodium channel inactivation", Clin Neurophysiol, 129, pp.694~706 (2018)
18. Argyriou AA, "Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study", Cancer, 119, pp.3570~3577 (2013)
19. Descoeur J, "Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors", EMBO Mol Med, 3, pp.266~278 (2011)
20. Argyriou AA, "Chemotherapy-induced peripheral neurotoxicity (CIPN): an update", Crit Rev Oncol Hematol, 82, pp.51~77 (2012)
21. Apostolidis L, "Dorsal root ganglia hypertrophy as in vivo correlate of oxaliplatin-induced polyneuropathy", PLoS One, 12, pp.e0183845~ (2017)
22. Kokotis P, "Oxaliplatin-induced neuropathy: a long-term clinical and neurophysiologic follow-up study", Clin Colorectal Cancer, 15, pp.e133~e140 (2016)
23. Loprinzi CL, "Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB", Alliance), 2014, pp.32, 997~1005
24. Glimelius B, "Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT)", Acta Oncol (Madr), 57, pp.393~402 (2018)
25. Smith EML, "Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy", JAMA, 309, pp.1359~ (2013)
26. Rowinsky EK, "Paclitaxel (taxol)", N Engl J Med, 332, pp.1004~1014 (1995)
27. Shimozuma K, "Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial", Support Care Cancer, 20, pp.3355~3364 (2012)
28. Gornstein EL, "Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects", Exp Neurol, 288, pp.153~166 (2017)
29. Matsumura Y, "The prophylactic effects of a traditional japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action", Mol Pain, 10, pp.61~ (2014)
30. Baldwin RM, "A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101", Clin Cancer Res, 18, pp.5099~5109 (2012)
31. Fernandes R, "Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review", Support Care Cancer, 24, pp.3633~3650 (2016)
32. Loprinzi CL, "The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism", Cancer J, 13, pp.399~403 (2007)
33. Fernandes R, "Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review", Support Care Cancer, 24, pp.1583~1594 (2016)
34. Tofthagen C, "Peripheral neuropathy caused by paclitaxel and docetaxel: an evaluation and comparison of symptoms", J Adv Pract Oncol, 4, pp.204~215 (2013)
35. Hilpert F, "Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin", paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group, 2005, pp.13, 797~805
36. Wadia RJ, "The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients", Oncotarget, 9, pp.7322~7331 (2018)
37. Richardson PG, "Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma", Blood, 116, pp.679~686 (2010)
38. Argyriou AA, "Bortezomib-induced peripheral neurotoxicity: an update", Arch Toxicol, 88, pp.1669~1679 (2014)
39. Pei XY, "Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors", Clin Cancer Res, 10, pp.3839~3852 (2004)
40. Giannoccaro MP, "Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study", Neurol Sci, 32, pp.361~363 (2011)
41. Chaudhry V, "Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy", J Peripher Nerv Syst, 13, pp.275~282 (2008)
42. Velasco R, "Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity:from pathogenesis to treatment", J Peripher Nerv Syst, 24, pp.S52~S62 (2019)
43. Kanbayashi Y, "Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis", Anticancer Drugs, 21, pp.877~881 (2010)
44. Callander N, "Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo", Cancer Chemother Pharmacol, 74, pp.875~882 (2014)
45. Richardson PG, "Management of treatment-emergent peripheral neuropathy in multiple myeloma", Leukemia, 26, pp.595~608 (2012)
46. Richardson PG, "Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline", Br J Haematol, 144, pp.895~903 (2009)
47. TAUSSIG HB, "A study of the German outbreak of phocomelia. The thalidomide syndrome", JAMA, 180, pp.1106~1114 (1962)
48. Bramuzzo M, "Thalidomide for inflammatory bowel disease", Medicine, 95, pp.e4239~ (2016)
49. Bolomsky A, "Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro", Exp Hematol, 42, pp.516~525 (2014)
50. Wani TH, "The dihydroxy metabolite of the teratogen thalidomide causes oxidative DNA damage", Chem Res Toxicol, 30, pp.1622~1628 (2017)
51. Ochonisky S, "Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients", Arch Dermatol, 130, pp.66~69 (1994)
52. Palumbo A, "Thalidomide for treatment of multiple myeloma: 10 years later", Blood, 111, pp.3968~3977 (2008)
53. Miltenburg NC, "Chemotherapy-induced neuropathy: a comprehensive survey", Cancer Treat Rev, 40, pp.872~882 (2014)
54. Canta A, "Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN)", Toxics, 3, pp.198~223 (2015)
55. Lavoie Smith EM, "Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia", J Peripher Nerv Syst, 20, pp.37~46 (2015)
56. Kuruvilla G, "The natural history of vincristine-induced laryngeal paralysis in children", Arch Otolaryngol Neck Surg, 135, pp.101~105 (2009)
57. Bacon LC, "Vincristine-induced vocal cord paralysis in a patient with acute lymphoblastic leukemia", Ann Hematol, 91, pp.971~972 (2012)
58. Chauvenet AR, "Vincristine-Induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a pediatric oncology group study", J Pediatr Hematol Oncol, 25, pp.316~320 (2003)
59. Moriyama B, "Adverse interactions between antifungal azoles and vincristine: review and analysis of cases", Mycoses, 55, pp.290~297 (2012)
60. Hirayama Y, "Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial", Int J Clin Oncol, 20, pp.866~871 (2015)
61. Hu LY, "Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms", Curr Neuropharmacol, 17, pp.184~196 (2019)
62. Kim BS, "Efficacy and safety of oxycodone", naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea, 2018, pp.14, e448~e454
63. Mishra S, "A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain", Am J Hosp Palliat Med, 29, pp.177~182 (2012)
64. Romero-Sandoval EA, "Peripherally restricted cannabinoids for the treatment of pain", Pharmacother J Hum Pharmacol Drug Ther, 35, pp.917~925 (2015)
65. Park SB, "Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity", J Peripher Nerv Syst, 24, pp.S13~S25 (2019)
66. Postma TJ, "The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20", Eur J Cancer, 41, pp.1135~1139 (2005)
67. Calhoun EA, "Psychometric evaluation of the functional assessment of cancer therapy", gynecologic oncology group-neurotoxicity (Fact, Int J Gynecol Cancer, pp.2003, 13[DOI]
68. Dubey D, "Severe neurological toxicity of immune checkpoint inhibitors:growing spectrum", Ann Neurol, 87, pp.659~669 (2020)

관련 논문AI추천